Vine Hill Capital Investment Corp. II VHCP Deferred offering costs

Deferred offering costs at other companies

Immix Biopharma, Inc.IMMX

$164.72K—

Bain Capital Specialty FinanceBCSF

$3.29M-24.2%

Nurix Therapeutics, Inc.NRIX

$100K0.0%

Mineralys Therapeutics, Inc.MLYS

$200K-33.3%

Sonida Senior LivingSNDA

$0—

Oaktree Specialty LendingOCSL

$43K-73.3%

Operating income-$437.0K—

Net income$1.6M—

EPS (diluted)$0.05—

Cash & equivalents$2.0M—

Total equity-$5.8M—

Total assets$234.9M—

Operating cash flow-$501.0K—

Market cap$306.05M+0.3%

Current ratio8.6×—

Reported directly by Vine Hill Capital Investment Corp. II in its filing.

Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.

The official record: Vine Hill Capital Investment Corp. II ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Vine Hill Capital Investment Corp. II 's deferred offering costs?: Vine Hill Capital Investment Corp. II (VHCP) reported deferred offering costs of $10.66M in Q1 2026.